Literature DB >> 30080720

Surgical Techniques and Long-term Outcomes of Living-donor Liver Transplantation With Inferior Vena Cava Replacement Using Atriocaval Synthetic Interposition Graft for Budd-Chiari Syndrome.

Young-In Yoon1, Sung-Gyu Lee1, Deok-Bog Moon1, Chul-Soo Ahn1, Shin Hwang1, Ki-Hun Kim1, Tae-Yong Ha1, Gi-Won Song1, Dong-Hwan Jung1, Gil-Chun Park1, Dong-Sik Kim2, Suk-Jung Choo3.   

Abstract

OBJECTIVE: We aimed to describe our living-donor liver transplantation (LDLT) surgical technique and its long-term patency for patients with Budd-Chiari syndrome (BCS) and retrohepatic inferior vena cava (IVC) obstruction that extends up to the atrium.
BACKGROUND: From a technical perspective, LDLT for BCS with an IVC obstruction up to the right atrium is one of the most challenging surgical procedures. Consequently, the optimal surgical technique for patients with BCS has not yet been elucidated.
METHODS: A durable LDLT technique without piggy-back hepatectomy was designed using a large-caliber synthetic interposition vascular graft between the right atrium and the infrahepatic IVC for reconstructing the hepatic outflow tract in patients with BCS.
RESULTS: Between May 2006 and May 2017, 5 of 17 BCS patients who underwent LDLT required the described technique. All patients with a median follow-up of 10.5 years (range, 9.2-11.5 years) demonstrated the patent IVC grafts and no recurrence of BCS.
CONCLUSIONS: Our refined technique does not require unnecessary and dangerous dissection of the diseased IVC, and eliminates the residual suprahepatic vena cava with the possibility of BCS recurrence by connecting the graft to the healthy atrium.

Entities:  

Year:  2019        PMID: 30080720     DOI: 10.1097/SLA.0000000000002847

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

Review 1.  Effects of remote ischemic preconditioning on liver injury following hepatectomy: a systematic review and meta-analysis of randomized control trials.

Authors:  Hao Zhang; Ting Zhang; Furui Zhong; Xianming Xia
Journal:  Surg Today       Date:  2021-01-19       Impact factor: 2.549

2.  Living Donor Liver Transplantation for Budd-Chiari Syndrome: A Propensity Score-Matched Analysis.

Authors:  V Gunasekaran; M S Reddy; A Rammohan; N Shanmugam; D Thiruchunapalli; R G Kanagavelu; I Kaliamoorthy; M Rela
Journal:  World J Surg       Date:  2022-09-07       Impact factor: 3.282

3.  Liver Transplantation and Budd-Chiari Syndrome: When the Cause Becomes the Solution.

Authors:  Nikolaos Garmpis; Christos Damaskos; Dionysios Prevezanos; Anna Garmpi; Vasiliki E Georgakopoulou; Efstathios A Antoniou; Gregory Kouraklis; Dimitrios Dimitroulis
Journal:  Maedica (Bucur)       Date:  2022-06

4.  Recipient hepatectomy under total hepatic vascular exclusion to prevent hepatocellular carcinoma spread in living donor liver transplantation.

Authors:  Young-In Yoon; Shin Hwang; Deok-Bog Moon; Dong-Hwan Jung; Sung-Gyu Lee
Journal:  Korean J Transplant       Date:  2021-06-07

5.  Living-donor liver transplantation in Budd-Chiari syndrome with inferior vena cava complete thrombosis: A case report and review of the literature.

Authors:  Vinicius Rocha-Santos; Daniel Reis Waisberg; Rafael Soares Pinheiro; Lucas Souto Nacif; Rubens Macedo Arantes; Liliana Ducatti; Rodrigo Bronze Martino; Luciana Bertocco Haddad; Flavio Henrique Galvao; Wellington Andraus; Luiz Augusto Carneiro-D'Alburquerque
Journal:  World J Hepatol       Date:  2021-01-27

6.  Patch venoplasty for resecting tumor invading the retrohepatic inferior vena cava using total and selective hepatic vascular exclusion.

Authors:  Sung-Min Kim; Shin Hwang; Deok-Bog Moon; Dong-Hwan Jung; Sung-Gyu Lee
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-11-30

7.  Resection of retrohepatic inferior vena cava without reconstruction in ex vivo liver resection and autotransplantation: a retrospective study.

Authors:  Xianwei Yang; Tao Wang; Junjie Kong; Bin Huang; Wentao Wang
Journal:  BMC Surg       Date:  2020-03-24       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.